Breast Cancer Clinical Trial
— PASAPASOfficial title:
Randomized Controlled Study Assessing the Feasibility and the Medico-economic Impact of Nutritional Intervention in Women With Breast Cancer Under Adjuvant Chemotherapy
Breast cancer is the most common cancer in women. Weight gain in adulthood, overweight or
obesity, physical inactivity and alcohol consumption are risk factors commonly associated
with risk of breast cancer (mainly for post-menopausal for overweight and obesity). Reduced
physical activity is one factor likely to weight gain in women after adjuvant chemotherapy
for localized breast cancer. Furthermore, physical activity appropriately could improve many
prognostic factors and survival of women after breast cancer. Adapted Physical Activity
(APA) could improve fitness, quality of life, body image, treatment compliance and reduce
fatigue.
After diagnosis of breast cancer, there is many possible risk factors of mortality or
morbidity related to nutritional factors available to management. These risks prevention
through management of these patients appears indispensable through an APA program.
Thus, the investigators propose to test the feasibility of implementing a program of dietary
intervention and APA to prevent the risk of weight gain (which affects more than half of
patients) and maintain and/or increase their level of physical activity during and after
adjuvant chemotherapy.
| Status | Completed |
| Enrollment | 60 |
| Est. completion date | July 2014 |
| Est. primary completion date | July 2014 |
| Accepts healthy volunteers | No |
| Gender | Female |
| Age group | 18 Years to 75 Years |
| Eligibility |
Inclusion Criteria: - Female, 18 years = age < 75 years - With an invasive, non-metastatic, histologically confirmed, first breast carcinoma - Requiring the prescription of a first line of adjuvant chemotherapy - Followed in the research center - Whose ability to participate in the APA intervention has been certified by a medical certificate issued by physician, the referring physician or the physician investigator - Residing within a radius of 60 km around the center investigator or agreeing to bear the travel costs beyond proposed reimbursement - Availability and willingness to invest in the PASAPAS study during the program (6 months) and during the post-program follow-up (6 months) - Able to understand, read and write French - Covered by a medical insurance - Written, signed informed consent Exclusion Criteria: - Female with metastatic or inflammatory breast cancer, - History or concomitant primary cancer (except for carcinoma in situ of the uterine cervix and/or skin basal cell carcinoma and or colon carcinoma in situ and/or not a breast cancer in complete response for at least 5 years) - Cons-indication to physical activity practice, at discretion of the investigator, - In a state of severe malnutrition according to the criteria of the High Authority for Health (HAS) 2010, namely: - Among women = 70 years: weight loss = 15% in 6 months or = 10% in 1 month - Among women > 70 years: weight loss = 15% in 6 months or = 10% in 1 month, body mass index < 18 kg / m² - History of eating disorders, - Not possible follow-up for medical, social, familial, geographical or psychological reasons, during the program (6 months) and during the post-program follow-up (6 months), - Deprived of their liberty by court or administrative decision, - Pregnant or nursing, of childbearing age without effective contraception during the study. |
Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Open Label
| Country | Name | City | State |
|---|---|---|---|
| France | Centre Leon Berard | Lyon Cedex 08 |
| Lead Sponsor | Collaborator |
|---|---|
| Centre Leon Berard | Association Lyonnaise de Logistique Posthospitalière, Cancéropôle Lyon Auvergne Rhône-Alpes, Fondation de France, Ligue du Rhône, Lions Club Bourg-en-Bresse et Pérouges, Ministère de la Recherche, National Cancer Institute, France |
France,
Holmes MD, Chen WY, Feskanich D, Kroenke CH, Colditz GA. Physical activity and survival after breast cancer diagnosis. JAMA. 2005 May 25;293(20):2479-86. — View Citation
Majed B, Moreau T, Senouci K, Salmon RJ, Fourquet A, Asselain B. Is obesity an independent prognosis factor in woman breast cancer? Breast Cancer Res Treat. 2008 Sep;111(2):329-42. Epub 2007 Oct 16. — View Citation
Newton RU, Galvão DA. Exercise in prevention and management of cancer. Curr Treat Options Oncol. 2008 Jun;9(2-3):135-46. doi: 10.1007/s11864-008-0065-1. Epub 2008 Aug 13. Review. — View Citation
Pierce JP, Stefanick ML, Flatt SW, Natarajan L, Sternfeld B, Madlensky L, Al-Delaimy WK, Thomson CA, Kealey S, Hajek R, Parker BA, Newman VA, Caan B, Rock CL. Greater survival after breast cancer in physically active women with high vegetable-fruit intake — View Citation
Trédan O, Bajard A, Meunier A, Roux P, Fiorletta I, Gargi T, Bachelot T, Guastalla JP, Lallemand Y, Faure C, Pérol D, Bachmann P. Body weight change in women receiving adjuvant chemotherapy for breast cancer: a French prospective study. Clin Nutr. 2010 Ap — View Citation
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Assessment in a cohort of adult patients with a 1st breast cancer non-metastatic, the feasibility of implementing an APA intervention during 6 months, in addition to a dietary management, concomitant to prescription of a first-line adjuvant chemotherapy | Proportion of patients who participate in at least two mandatory APA sessions by week during all the APA program, except during the 1st week of each course of CT | 6 months | No |
| Secondary | Assessment of patients compliance to the implementation of the APA program and analyze of the reasons for noncompliance | Rate of patients who completed the full program and analysis of non-compliance grounds during the program | 6 months | No |
| Secondary | Assessment of acceptability of the intervention and randomization / recruiting capabilities | Number of patients contacted by the investigator to participate in the study and rate of patients randomized | 6 months | No |
| Secondary | Verification of adequacy between the conduct procedures of program (APA and dietetic) and the constraints of program implementing in real conditions | Formalization of a program used in real conditions | 12 months | No |
| Secondary | Description of patient satisfaction | Calculation of overall satisfaction score of patients on the treatment received, evaluated by a scale of satisfaction | Month 12 | No |
| Secondary | Medico-economic impact of the intervention | Settlement expenses costs, incurred costs and costs avoided by the intervention | 12 months | No |
| Secondary | Biological study | Analyses of metabolomic profiles and adipokines expression linked to breast cancer at initial diagnosis (before surgery) and description of metabolism changes during nutritional interventions and therapeutic care | Day 1 CT, week 9, week 24, month 12 | No |
| Secondary | Description of dietary | Collection of patient nutritional intake during 3 days by self-administered questionnaire | Day 1 CT, week 24, month 12 | No |
| Secondary | Description of level and pattern physical activity | Evaluation of level and pattern physical evaluation (PAQAP and IPAQ questionnaire) | Day 1 CT, Week 9, Week 24, Month 12 | No |
| Secondary | Description of anthropometry | Measurement of weight, height, waist and hip circumference | Day 1 CT, week 9, week 24, month 12 | No |
| Secondary | Description of lipid profiles | Measurement of total cholesterol, HDL, LDL and triglycerides | Day 1 CT, week 9, week 24, month 12 | No |
| Secondary | Assessment of life quality | Life quality scores calculation (QLQ-C30, BR-23, MOS SF-36) | Day 1 CT, week 24, month 12 | No |
| Secondary | Description of anxiety | score calculation of anxiety (STAI questionnaire) | Day 1 CT, week 24, month 12 | No |
| Secondary | Assessment of patients compliance to the implementation of diet and analyze of the reasons for noncompliance | Rate of patients who completed the full program and analysis of non-compliance grounds during the program | 6 months | No |
| Secondary | Description of body satisfaction | score calculation of QSCPGS questionnaire | Day 1 CT, week 24, month 12 | No |
| Secondary | Description of body composition | Measurement of body composition by impedancemetry | Day 1 CT, week 9, week 24, month 12 | No |
| Secondary | Description of self-perception | score calculation of self-perception (QSCPGS questionnaire) | Day 1 CT, week 24, month 12 | No |
| Secondary | Description of self esteem | score calculation of self-esteem (Rosenzweig scale) | Day 1 CT, week 24, month 12 | No |
| Secondary | Description of depression | score calculation of depression (BDI questionnaire) | Day 1 CT, week 24, month 12 | No |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04681911 -
Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer
|
Phase 2 | |
| Terminated |
NCT04066790 -
Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
|
Phase 2 | |
| Completed |
NCT04890327 -
Web-based Family History Tool
|
N/A | |
| Completed |
NCT03591848 -
Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility
|
N/A | |
| Recruiting |
NCT03954197 -
Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients
|
N/A | |
| Terminated |
NCT02202746 -
A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer
|
Phase 2 | |
| Active, not recruiting |
NCT01472094 -
The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
|
||
| Completed |
NCT06049446 -
Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
|
||
| Withdrawn |
NCT06057636 -
Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study
|
N/A | |
| Recruiting |
NCT05560334 -
A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations
|
Phase 2 | |
| Active, not recruiting |
NCT05501769 -
ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT04631835 -
Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer
|
Phase 1 | |
| Completed |
NCT04307407 -
Exercise in Breast Cancer Survivors
|
N/A | |
| Recruiting |
NCT03544762 -
Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation
|
Phase 3 | |
| Terminated |
NCT02482389 -
Study of Preoperative Boost Radiotherapy
|
N/A | |
| Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
| Completed |
NCT00226967 -
Stress, Diurnal Cortisol, and Breast Cancer Survival
|
||
| Recruiting |
NCT06019325 -
Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy
|
N/A | |
| Recruiting |
NCT06037954 -
A Study of Mental Health Care in People With Cancer
|
N/A | |
| Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 |